## IPCA Laboratories Limited (IPCALAB) Stock Analysis - December 20, 2024

This report analyzes the provided data for IPCA Laboratories Limited (IPCALAB) to determine whether it is a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Company Profile:**

* **Symbol:** IPCALAB
* **Company Name:** IPCA Laboratories Limited
* **Industry:** Pharmaceuticals
* **Listing Date:** February 8, 1995
* **ISIN:** INE571A01038


**2. Key Indicators:**

**2.1 Current Price Analysis:**

| Metric             | Value      |
|----------------------|------------|
| Last Price          | 1,585.00   |
| Change              | -9.95      |
| PChange (%)         | -0.62%     |
| Previous Close      | 1,594.95   |
| Open                | 1,607.95   |
| Close               | 1,582.50   |
| VWAP                | 1,600.08   |
| Week High           | 1,708.65   |
| Week Low            | 1,041.00   |
| Sector PE           | 64.62      |
| Symbol PE           | 60.4       |


* The current price is down slightly from the previous close and open, indicating some downward pressure. However, it remains significantly above the week's low and well within the week's high and low range.  The pre-open market shows a higher opening price than the actual open, suggesting some selling pressure at the market open.

**2.2 Financial Performance (Last Five Quarters):**

| Quarter Ending     | Income       | Expenditure  | Profit After Tax | Diluted EPS |
|----------------------|--------------|---------------|-------------------|-------------|
| 30-Sep-2024 (U)    | 182,794      | 148,873       | 24,412           | 9.62        |
| 30-Jun-2024 (U)    | 158,125      | 129,336       | 20,413           | 8.05        |
| 31-Mar-2024 (A)    | 152,572      | 130,410       | 6,476            | 2.55        |
| 31-Dec-2023 (U)    | 152,372      | 132,357       | 13,694           | 5.4         |
| 30-Sep-2023 (U)    | 169,881      | 145,368       | 16,213           | 6.39        |

*(U) - Un-Audited, (A) - Audited*

* Revenue shows some fluctuation but generally remains relatively stable over the past five quarters.
* Profit after tax shows significant variation, with a notable dip in Q1 2024 (March 31, 2024).  This requires further investigation into the reasons for this decline.
* Diluted EPS follows a similar trend to profit after tax.

**2.3 Shareholding Analysis:**

| Quarter Ending     | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|----------------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023         | 46.29%                     | 53.71% | 0.00%                         | 100.00%|
| 31-Dec-2023         | 46.29%                     | 53.71% | 0.00%                         | 100.00%|
| 31-Mar-2024         | 46.30%                     | 53.70% | 0.00%                         | 100.00%|
| 30-Jun-2024         | 46.30%                     | 53.70% | 0.00%                         | 100.00%|
| 30-Sep-2024         | 46.30%                     | 53.70% | 0.00%                         | 100.00%|

* Promoter holding has remained remarkably stable over the past year, indicating strong internal confidence.

**2.4 Corporate Action Summary:**

* **Interim Dividend:** Rs 2 per share (ex-date: November 27, 2024)
* **Past Dividends:**  A history of regular dividend payments is evident from the data, showing consistent payouts.  Note the significant dividend of Rs 8 per share in November 2021, followed by a stock split.

**2.5 Volatility and Risk:**

* **CM Daily Volatility:** 1.72 (This metric needs context; a comparison to industry averages would be beneficial.)
* **CM Annual Volatility:** 32.86 (This metric needs context; a comparison to industry averages would be beneficial.)
* The relatively high annual volatility suggests a higher risk profile compared to less volatile stocks.

**2.6 Key Directors and Contact Info:**

* **Registrar:** Link Intime India Private Limited
* **Company Contact:** 48, Kandivli Industrial Estate, Kandivili (W), MUMBAI - 400067
* **Key Personnel:**  (List of directors and their designations are available in the provided data but omitted here for brevity.  This information can be easily extracted.)


**3. Recent Announcements:**

* Several recent announcements mention "Spurt in Volume," suggesting increased trading activity.  Other announcements relate to general updates, newspaper publications, investor meetings, and revised record dates.  These announcements, while not providing specific financial information, indicate ongoing activity and communication from the company.


**4. Final Verdict:**

Based solely on the provided data, the verdict is **Hold**.

**Reasoning:**

* While the company shows a history of dividend payments and relatively stable promoter holdings, the recent dip in profit after tax in Q1 2024 raises concerns.  Further investigation into the causes of this decline is crucial before considering a buy recommendation.  The relatively high volatility also adds to the risk.  The current price is within a reasonable range considering the week's high and low, suggesting a period of consolidation might be appropriate before making a decisive buy or sell decision.

**Conclusion:**

IPCA Laboratories Limited presents a mixed picture.  Positive aspects include consistent dividend payments and stable promoter holdings. However, the recent decline in profitability and relatively high volatility warrant a cautious approach.  More information is needed to assess the long-term prospects and justify a buy recommendation.  A "Hold" recommendation allows for further observation and analysis before making a more informed investment decision.
